about
Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodesPET Imaging in Patients with Meningioma - Report of the RANO/PET Group.Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification.Leptomeningeal metastases: a RANO proposal for response criteria.Leptomeningeal metastases of solid cancer.Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases.European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma.Lomustine and Bevacizumab in Progressive Glioblastoma.Farewell to monomodality treatment in patients with WHO lower grade glioma?Evidence-based management of adult patients with diffuse glioma - Authors' reply.Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.Close follow-up after discontinuation of cyproterone acetate: a possible option to defer surgery in patients with voluminous intracranial meningioma.Chemical meningitis related to intra-CSF liposomal cytarabine.Occurrence of vismodegib-induced cramps in the treatment of basal cell carcinoma: a prospective study in 30 patients.Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe.Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site.Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.The Evolving Landscape of Brain Metastasis.[Recommendations for the organ donation from patients with brain or medullary primitive tumors on behalf of the Association of the Neuro-oncologists of French Expression (ANOCEF) and the Club of Neuro-oncology of the French Society of Neurosurgery].Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).How we treat patients with leptomeningeal metastases.Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitisProfound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibitionComplementary and alternative medicine use in glioma patients in FranceHow we treat glioblastoma
P50
Q33913936-B2E8D765-8877-49C8-833B-4C40565A273AQ34682187-90BC0990-87E3-4F84-99D6-F02180CB5ED6Q36204942-9A1AFDE1-9DDC-4DDC-9F4C-4595C20D5C73Q36236770-660A06D9-791C-464C-9A65-3B1F0525B60CQ38962528-E5DA3557-9747-4835-95E3-892B669D74EAQ39126735-700B3B69-4E0B-4544-A02F-395924F558DAQ39291912-FEBD112E-20C8-4E98-8A6B-A5C308DDF5BFQ39359091-56499CC3-8461-4C40-A306-3173261CB3F8Q47399678-75DE8AB5-C652-4AB5-B5FC-A209B8BA8F71Q47916377-C7DFCC03-E9A4-4611-A643-FC19E671141DQ48172740-7C943C94-55EB-4FA0-BE3F-1B4A8405E5B7Q48225182-ECFE9100-FD07-45EF-804F-C0D98E115E8BQ48426567-90310EB2-D8E7-4D4D-8986-B1A6CD292107Q50066702-48EFBC08-EC8B-4386-973B-1262197BB570Q50083570-52B39416-6D95-4DE7-A212-C3AE41EF5F5CQ52096930-5A449F60-2AA5-4A7A-8362-A33554FC8C6EQ52574177-53ABADCE-0F11-4357-8344-54AD29F31765Q52672321-8B548325-4588-499C-B33C-081B30977488Q52673453-BAA05CE5-F9E1-4801-86A9-00DF67FDA0E1Q52865062-F3364273-FDAB-4BDD-9DB2-5DA0067475D0Q55029808-7CF44AAF-3886-45E4-9A52-23F2E030DE10Q64955303-71CD6AE1-E3A3-40AB-8D3A-2A02FA2DEB5CQ88318731-3FD7C28A-12EB-411D-AD79-C9CB9E23EAE0Q90484316-2D7A4F09-1227-4DBC-BEBE-49032AB7249AQ90865808-902B15E9-96AB-4807-BB91-AF1D98F458EDQ91812608-DB5337F3-BB91-4ABB-9204-3AF50FB719B6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Emilie Le Rhun
@ast
Emilie Le Rhun
@en
Emilie Le Rhun
@es
Emilie Le Rhun
@nl
type
label
Emilie Le Rhun
@ast
Emilie Le Rhun
@en
Emilie Le Rhun
@es
Emilie Le Rhun
@nl
prefLabel
Emilie Le Rhun
@ast
Emilie Le Rhun
@en
Emilie Le Rhun
@es
Emilie Le Rhun
@nl
P106
P31
P496
0000-0002-9408-3278